Researchers Optimistic About Alzheimer's Vaccine

[Max]

Researchers Optimistic About Alzheimer's Vaccine
By Will Dunham

WASHINGTON (Reuters) - A new vaccine blocked the development of Alzheimer's disease (news - web sites) in mice genetically engineered to carry a human gene for the degenerative brain disease, researchers said on Thursday.

Researchers at New York University School of Medicine said they expected to test the vaccine in initial human clinical trials within a year. They also expressed optimism that the vaccine would prove to be safer than another one already being tested in human clinical trials.

``The potential for vaccination as a therapeutic approach for Alzheimer's disease is something that's very exciting,'' Dr. Thomas Wisniewski, an author of the study, said in an interview. ``But this (new vaccine) is a particularly good line of investigation. And it looks like it will be translated very rapidly to human use.''

Alzheimer's disease is characterized by the destruction of nerve cells, especially in the areas of the brain responsible for memory and learning. Abnormal structures in the brain called plaques are one of the hallmarks of the disease. As the plaques accumulate, nerve cell connections are reduced. The plaques are made up of deposits of a protein called amyloid beta, which is toxic to cells and can damage and kill them.

Wisniewski and colleagues Dr. Blas Frangione and Einar Sigurdsson injected the new vaccine into 11-month-old mice that had been genetically engineered with a human gene for Alzheimer's disease. At that age, the mice already had formed amyloid plaques in the brain. Seven months later, the researchers examined the brains of the mice.

They found that the amount of amyloid plaque was reduced by 89% in the cortex, the center of higher thought, and by 81% in the hippocampus, the memory center, compared with the brains of mice that also had been genetically engineered but were not given the vaccine. The vaccinated mice also had 57% less of the protein that fosters the development of amyloid plaque.

The study appears in the American Journal of Pathology.

Four million Americans have Alzheimer's disease, including one in 10 of people over age 65 and nearly half of those over 85, according to the Alzheimer's Association. The group said that without a cure or prevention, the number will jump to 14 million by 2050.

Alzheimer's is a progressive, degenerative brain disease whose victims experience confusion, personality and behavior changes and impaired judgment. Most people with Alzheimer's disease become unable to care for themselves.

The vaccine already in human clinical trials showed promise in mice less than two years ago. That vaccine is made of a fragment of amyloid-precursor protein.

Wisniewski expressed concern that the make-up of the first vaccine could be toxic to nerve cells in the brain and by itself may lead to the development of plaque.

In previous studies, the NYU team blocked the formation of amyloid plaque in the brains of rats by creating a short peptide, a fragment of a protein. This peptide prevented the formation of a toxic, insoluble form of amyloid that is deposited in plaques in the brain.

The new vaccine is based on a modified, nontoxic peptide, the researchers said.

``We believe that our peptide vaccine isn't toxic to nerve cells because it doesn't aggregate into clumps; it remains in solution,'' Frangione said.

Wisniewski said he hoped the new vaccine could be ``a much more appropriate choice for future human studies'' than the one already being tested. He said the NYU team is looking for a corporate partner as the vaccine moves into human trials.

``The hope here in particular is that this will work well because the effect in the animal model is so dramatic, and also because the amyloid lesions that you have in the animals are so similar to what you have in humans,'' Wisniewski said.

[wilfried]

Max,

Elan is already going into phase 2 testing on over 300 people, after phase 1 proved the vaccine safe:

Alzheimer's vaccine passes key test:

http://edition.cnn.com/2001/HEALTH/0...ine/index.html

[Max]

Thanks Wilfred,

I got a older friend whose wife has it...

I wonder why it takes so long to test something like this on sci?

[Chris Chappell]

A preventive vaccine for SCI Max?

Wow, cool idea . Especially for those people who will be injured tomorrow and the next day, and the next....

If science could prevent them from getting SCI by giving them a vaccine that would be awesome. A lot less members of this club that noone wants to belong to.

Good article though.

[Max]

Chris,

It already exist for sci,,Wise will correct me,but I belive Dr.Sam David from Montreal found it...

But he still testing it only on rats

[Max]

David, Samuel

Center for Research in Neuroscience
Montreal General Hospital Research Institute
1650 Cedar Ave.,, Montreal, Quebec, Canada, H3G 1A4
937-6011
sdavid11@po-box.mcgill.ca


Recruiting the immune response to neutralize axon growth inhibitors and promote regeneration in the adult mammalian CNS.

Axon growth inhibitors associated with myelin block neurite growth and axon regeneration. Some of these inhibitors have been identified and other inhibitory activities have yet to be characterized. We have used both active and passive immunization approaches to block these inhibitors to promote long distance axon regeneration. In the active immunization approach adult mice were immunized with purified myelin or myelin-rich tissue in incomplete Freund's adjuvant for 3 weeks prior to a spinal cord dorsal hemisection. Anterograde and retrograde labeling techniques showed long distance regeneration of a substantial number of corticospinal fibers. Similarly, anterograde labeling via the sciatic nerve showed long distance regeneration of ascending sensory fibers. This effect is mediated via blocking antibodies, although contribution of other effects cannot be ruled out. In the passive immunization approach, mice received an intra-peritoneal injection of anti-myelin mouse antiserum within 30 minutes after a spinal cord dorsal hemisection and treated again 7 days later. Long distance regeneration of the corticospinal tract was detected 3 weeks later. The large number of axons that regenerate is likely due to the blocking of multiple myelin-associated inhibitors. These vaccine approaches show that blocking myelin-associated inhibitors can promote regeneration of long fiber tracts.